Download Pharmacology of Antivirals for HZV and VSV Skin Infections

Pharmacology of Antivirals for HZV and VSV Skin Infections – Practice Questions
Block 7 - Pharmacology
1. Which of the following correctly describes the mechanism of action for nucleoside analogues
for the treatment of viral skin infections?
A. Nucleoside analogues are converted to nucleotide triphosphates and competitively
inhibit viral DNA polymerase.
B. Nucleoside analogues are converted to nucleotide triphosphates and competitively
inhibit viral RNA polymerase.
C. Nucleoside analogues are converted to nucleotide triphosphates and competitively
inhibit host cell DNA polymerase.
D. Nucleoside analogues are converted to nucleotide triphosphates and competitively
inhibit host cell RNA polymerase.
E. Nucleoside analogues are converted to ribonucleotide triphosphates and competitively
inhibit viral RNA polymerase.
2. Which of the following antiviral medications would be most toxic to a patient in renal failure?
A.
B.
C.
D.
3.
Acyclovir
Famciclovir
Pentciclovir
Valacyclovir
The most common side effect reported by patients when using topical antimicrobials is…
A.
B.
C.
D.
E.
Headache
Nausea
Vomiting
Steven-Johnson’s Syndrome
Application site reactions
4. Which of the following statements is true concerning the concomitant use of corticosteroids
with antivirals?
A. Concomitant use of corticosteroids and antivirals has been shown to resolve postherpetic neuritis.
B. Concomitant use of corticosteroids and antivirals has been shown to resolve acute
neuritis.
C. Concomitant use of corticosteroids and antivirals has been shown to shorten VZV
infection.
D. Concomitant use of corticosteroids and antivirals has been shown to shorten HSV
infection.
E. Concomitant use of corticosteroids and antivirals has been shown to resolve postherpetic neuritis and acute neuritis.
1
Pharmacology of Antivirals for HZV and VSV Skin Infections – Practice Questions
Block 7 - Pharmacology
5. Which of the following best describes the mechanism of action of Docosanol?
A. Inhibition of fusion between the HSV capsid and the HSV envelope preventing viral
entry.
B. Inhibition of fusion between the plasma membrane and the HSV capsid preventing viral
entry.
C. Inhibition of fusion between the plasma membrane and the HSV envelope preventing
viral entry.
D. Inhibition of fusion between the plasma membrane and the HSV envelope preventing
vial assembly before budding.
E. Inhibition of fusion between the plasma membrane and the HSV capsid preventing viral
assembly before budding.
2